The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.

@article{Kimple2015ThePV,
  title={The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.},
  author={Randall J. Kimple and Paul M. Harari},
  journal={Annals of translational medicine},
  year={2015},
  volume={3 Suppl 1},
  pages={
          S14
        }
}
In a recent issue of Radiotherapy and Oncology, Lohaus and colleagues reported (http://dx.doi.org/10.1016/ j.radonc.2014.11.011) on a subgroup analysis from the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) (1). They reported on 221 patients treated with postoperative radiotherapy with concurrent cisplatin (PORT-C) treated over a 5-year period between 2005 and 2010. They investigate the role of human papilloma virus (HPV) in non-oropharynx head and neck cancer and extend findings… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage.

  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2014
VIEW 1 EXCERPT

Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 1 EXCERPT

p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…